Cancer antigen-125 useful biomarker for preeclampsia severity?
India: A recent case-control study published in The Journal of Obstetrics and Gynecology of India explored the potential of cancer Antigen-125 (CA-125) as a biomarker for predicting and correlating with the severity of preeclampsia.
The researchers found higher levels of serum CA-125 in the severe preeclampsia group versus the normotensive and non-severe preeclampsia group, but the difference was not statistically significant.
Preeclampsia is a potentially dangerous pregnancy complication characterised by high BP and is often associated with unfavourable feto-maternal outcomes. There is a lack in its pathophysiology, emphasizing the need to research for tests that can correlate with or predict the severity of preeclampsia.
Cancer antigen-125 is a readily available, simple biomarker with evidence of its secretion at the choriodecidual unit and may have a possible role. Pooja Bhatia, Department of Obstetrics and Gynaecology, Government Medical College and Hospital, Chandigarh, India, and colleagues compared serum CA-125 levels between normal pregnant women and women with preeclampsia. They determined its clinical usefulness in correlating with preeclampsia severity.
For this purpose, the researchers conducted a case-control study involving 58 women with preeclampsia. they were further divided into severe and non-severe groups and 62 gestational age-matched healthy, pregnant controls. A comparison was drawn of the serum CA-125 levels between the two groups.
The study revealed the following findings:
· The mean serum CA-125 in the controls was 16.44 ± 8.28 IU/ml, 13.82 ± 9.18 IU/ml in the non-severe and 23.55 ± 30.55 IU/ml in the severe pre-eclampsia group.
· Serum CA-125 had a significant association with systolic blood pressure (SBP), foetal growth restriction, diastolic blood pressure (DBP), pre-term birth and a highly significant association with 24-h urinary protein, liver enzymes, placental abruption, need for maternal intensive care as well as with poor neonatal outcome including stillbirth and neonatal mortality.
"More studies on a larger scale are needed to prove the usefulness of this marker concerning perinatal and maternal outcome and its association with pre-eclampsia and its severity," the researchers concluded.
Reference:
Bhatia, P., Goel, P., Mehra, R. et al. Correlation of Serum Cancer Antigen-125 (CA-125) Levels with Severity of Pre-eclampsia. J Obstet Gynecol India (2023). https://doi.org/10.1007/s13224-023-01869-2
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.